An interventional study of Psychoeduation for FHA and Treatment as Usual (TAU) in Hypothalamic Amenorrhea, Functional, sponsored by Karolinska Institutet. Not yet recruiting at 1 site in Sweden. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn whether a 10-week digital psychoeducational health and lifestyle program can help women with functional hypothalamic amenorrhea (FHA) recover ovulatory menstrual cycles and endocrine function.
The main questions the study aims to answer are:
Does the program increase the proportion of women who have at least one spontaneous ovulatory menstrual cycle within 12 months? Does it improve hormonal markers of recovery of the hypothalamic-pituitary-ovarian axis, such as LH, FSH, estradiol and T3? Does it improve psychological well-being, stress and eating-related symptoms?
Researchers will compare the program with usual care to see whether the structured program leads to faster or more frequent recovery of menstrual and endocrine function than the care women typically receive today.
Participants will:
Be randomly assigned to the 10-week digital self-help program, delivered via the Swedish healthcare platform 1177 with one module per week (intervention group), or to usual care with a consultation with a gynecologist (comparison group); the comparison group is offered the program after the study Complete questionnaires and a structured diagnostic interview Provide blood samples to measure hormone levels at 3, 6, 9 and 12 months Contact the clinic if menstrual bleeding occurs, so that a blood sample can confirm ovulation Have a gynecological examination with ultrasound after 12 months to assess ovarian activity and endometrial thickness
This study builds on an ongoing feasibility study (NCT07589868) and will help determine whether the program is effective and should be offered more widely to women with FHA.
The study is a randomized, controlled trial with multicentre recruitment evaluating a 10-week digital psychoeducational health and lifestyle program with 12 months of follow-up in women with functional hypothalamic amenorrhea (FHA).
Background and Significance FHA is a functional endocrine condition that can be reversed through behavioural and lifestyle changes. A structured psychoeducational program may support these changes by improving knowledge, motivation and self-management skills. The program is compared with usual care to determine whether it leads to superior restoration of ovulatory menstrual cycles and endocrine function.
Study Aim To evaluate whether a 10-week digital psychoeducational program, compared with usual care, increases the proportion of women with FHA who recover spontaneous ovulatory menstrual cycles within 12 months.
Study Setting and Participants Seventy women aged 18-40 years with FHA (amenorrhea for ≥3 months and with a hypothalamic hormone profile: FSH \<10 IU/L, LH \<10 IU/L and estradiol \<200 pmol/L after exclusion of other causes of amenorrhea) are recruited through several gynecological clinics, with central coordination at Karolinska University Hospital. Individuals who meet exclusion criteria receive appropriate clinical information, standard care or referral to relevant healthcare services.
Intervention and Comparator The intervention is a 10-week self-help program delivered via the Swedish healthcare platform 1177 (Stöd och behandling) with one module per week and no therapist support. The comparison group receives usual care, including a consultation with a gynecologist with standard information about FHA, and is offered the program after the 12-month follow-up.
Sample Size In the only previous randomized trial (Berga et al. 2003), ovarian activity recovered in 87.5% of women receiving individual cognitive behavioural therapy compared with 25% with observation. Because small trials tend to overestimate effects, and because the present intervention is a digital self-help program with a stricter primary outcome, a difference of 60% versus 25% is assumed. With 80% power and two-sided α = 0.05, 30 evaluable participants per arm are required. Allowing for 15% attrition, 35 participants per arm (70 in total) will be randomized.
Study Design and Assessments Two-arm, parallel-group superiority trial with 1:1 allocation. Randomization is performed centrally by Karolinska Trial Alliance, stratified by FHA severity at baseline (severe: estradiol \<80 pmol/L and LH \<2.4 IU/L), with randomly varying block sizes. At the screening visit, all individuals complete the DIAMOND screening questions and the complete eating disorder module, with further modules after a positive screening question. Validated questionnaires (including EDE-Q, PSS-14, GAD-7, PHQ-9, WHO-5, ISI, IPAQ and FSFI-6) and blood sampling (LH, FSH, estradiol, T3 and other hormones) are performed at baseline and at 3, 6, 9 and 12 months, with gynecological follow-up by video or in person. A gynecological examination with transvaginal ultrasound is performed at 12 months.
Data and Sample Collection Questionnaire data are collected electronically via REDCap. Findings from the feasibility study (NCT07589868) and the qualitative interview study inform the final protocol. Participants contact the clinic if menstrual bleeding occurs, and serum progesterone is measured on cycle day 21, counting the first day of bleeding as day 1, to assess ovulation.
Outcome Measures The primary outcome is the proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above [threshold] nmol/L) within 12 months. Secondary outcomes include time to first ovulatory cycle, number of spontaneous cycles, sustained recovery (≥3 consecutive cycles), change in LH, FSH, estradiol and T3, ultrasound signs of ovarian activity, psychological symptoms and well-being, and adverse events.
Statistical Analysis The primary analysis follows the intention-to-treat principle and compares the proportion with at least one spontaneous ovulatory cycle between groups, with the risk difference and 95% confidence interval and logistic regression adjusted for the stratification factor. Missing primary outcome data are handled with multiple imputation, with complete-case and worst-case sensitivity analyses. Secondary menstrual outcomes are analyzed with time-to-event methods and longitudinal outcomes with methods for repeated measurements. A detailed statistical analysis plan will be finalized before database lock.
Ethical Considerations Informed consent is obtained from all participants. The project is approved by the Swedish Ethical Review Authority (Dnr 2023-05586-01, with amendments 2025-07620-02 and 2026-06250-02). The overall risk to participants is considered low, and adverse events are monitored throughout the study period.
80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.
This study's planned enrollment of 70 is above the median of 54 across 49 interventional studies indexed under Amenorrhea.
Browse Amenorrhea studies →Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months.
Behavioral: Psychoeduation for FHA
Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months; access to the program offered after 12 months.
Other: Treatment as Usual (TAU)
HEAL-FHA digital psychoeducational program. 10-week self-help program delivered via 1177 Stöd och behandling (BankID), one module per week, addressing energy availability, exercise and stress. Follow-up at 3, 6, 9 and 12 months.
Usual care plus study follow-up: initial consultation with a gynecologist with standard information about FHA; the same assessments at 3, 6, 9 and 12 months.
Number of participants with return of spontaneous menstrual bleeding within 12 months from baseline.
Proportion of participants with at least one spontaneous ovulatory menstrual cycle (spontaneous bleeding without hormonal treatment and serum progesterone above 13 nmol/L. \[Time frame: 12 months\].
Time frame: Restoration of menstruation after 12 months of follow-up from baseline.
Time to spontaneous ovulatory cycles within 12 months from baseline.
Time to first spontaneous ovulatory cycle; number of spontaneous cycles; sustained recovery (≥3 consecutive spontaneous cycles)
Time frame: Baseline to 12 months
Change in BMI within 12 months from baseline.
Weight and height will be combined to report BMI in kg/m\^2
Time frame: 6 and 12 months from baseline
Change in serum luteinizing hormone (LH)
Change from baseline in serum luteinizing hormone (LH).
Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
Change in serum follicle-stimulating hormone (FSH)
Change from baseline in serum FSH (IU/L).
Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
Change in serum estradiol (E2)
Change from baseline in serum estradiol (pmol/L), sensitive LC-MS/MS method.
Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
Change in serum triiodothyronine (T3)
Change from baseline in serum T3 (\[nmol/L or pmol/L, if free T3 - check with the laboratory\]).
Time frame: Baseline to 12 months (also assessed at 3, 6 and 9 months)
Change in eating disorder symptoms (EDE-Q)
Change from baseline in Eating Disorder Examination Questionnaire 6.0 global score (range 0-6; higher scores indicate more symptoms).
Time frame: Baseline to 12 months
Change in perceived stress (PSS-14)
Change from baseline in Perceived Stress Scale total score (range 0-56; higher scores indicate more stress).
Time frame: Baseline to 12 months
Change in anxiety symptoms (GAD-7)
Change from baseline in GAD-7 total score (range 0-21; higher scores indicate more anxiety).
Time frame: Baseline to 12 months
Change in depressive symptoms (PHQ-9)
Change from baseline in PHQ-9 total score (range 0-27; higher scores indicate more depressive symptoms).
Time frame: Baseline to 12 months
Change in well-being (WHO-5)
Change from baseline in WHO-5 percentage score (range 0-100; higher scores indicate better well-being).
Time frame: Baseline to 12 months
Plan to share: Yes — What data will be shared: De-identified individual participant data collected during the trial, including: Demographics (age, sex) Clinical assessments and questionnaire responses Hormonal measurements (LH, estradiol, progesterone) Menstrual cycle and ovulation data Psychological and behavioral assessments Other documents to be shared: Data dictionary describing all variables and coding used Study protocol and statistical analysis plan
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: When data will become available and for how long: Data will be available 6 months after publication of the primary trial results and will remain accessible for 5 years.
Access criteria: By what access criteria: Data will be available to qualified researchers for scientific purposes following submission of a research proposal and approval by the trial steering committee. Requests should be sent to the corresponding author or data custodian (contact information provided in the study publication).Data will be shared via a secure data repository
No publications or documents are linked to this record.
Start is estimated for Sep 2027; primary completion for Sep 2028, 12 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Feb 2026 → Sep 2027, primary completion Jan 2028 → Sep 2028 and completion Dec 2028 → Dec 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.